Abstract
Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 180-185 |
| Number of pages | 6 |
| Journal | Korean Journal of Microbiology and Biotechnology |
| Volume | 40 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2012 Sep 1 |
Fingerprint
Keywords
- Antidiabetic drugs
- Incretin therapy
- Type 2 diabetes
ASJC Scopus subject areas
- Biotechnology
- Applied Microbiology and Biotechnology
- Microbiology
Cite this
Trends and perspectives in the development of antidiabetic drugs for type 2 diabetes mellitus. / Lee, Soo Hyun; Lee, Jong Keun; Kim, Ik Hwan.
In: Korean Journal of Microbiology and Biotechnology, Vol. 40, No. 3, 01.09.2012, p. 180-185.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trends and perspectives in the development of antidiabetic drugs for type 2 diabetes mellitus
AU - Lee, Soo Hyun
AU - Lee, Jong Keun
AU - Kim, Ik Hwan
PY - 2012/9/1
Y1 - 2012/9/1
N2 - Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.
AB - Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.
KW - Antidiabetic drugs
KW - Incretin therapy
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84867774450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867774450&partnerID=8YFLogxK
U2 - 10.4014/kjmb.1205.05012
DO - 10.4014/kjmb.1205.05012
M3 - Article
AN - SCOPUS:84867774450
VL - 40
SP - 180
EP - 185
JO - Korean Journal of Microbiology and Biotechnology
JF - Korean Journal of Microbiology and Biotechnology
SN - 1598-642X
IS - 3
ER -